Abstract:ID 129693 Poster Board 492 Animal testing for drug discovery is expensive and the decision to test a compound in an animal model should be carefully considered. In addition, the FDA Modernization Act has resulted in the allowance of alternatives to animal models for testing the safety and efficacy of drug candidates. Among these alternatives are human tissue models that provide a human-relevant context. Specialized cell types can be produced from primary human cells and used for basic research and drug discovery purposes. One of these is a 3D model for respiratory disease research, consisting of human-derived tracheal/bronchial epithelial cells. Though this translational Human Airway Epithelial (HAE) model is currently being employed by many researchers, this work is primarily done using individual tissue inserts placed in 6-well plates. This low-throughput approach is labor-intensive, time-consuming and expensive (high cost per each compound screened). We have established a high-throughput HAE assay that can be used for compound screening to advance respiratory virus programs. This is significant as it allows a higher number of compounds to be evaluated before being tested in vivo, allowing a more comprehensive comparison of candidates at this later discovery stage. We developed 96-well assays to evaluate compounds for Influenza, Respiratory Syncytial Virus (RSV) and Coronaviruses (including BSL-3 strains such as SARS-CoV-2), and these assays are easily adaptable to other respiratory viruses like Human metapneumovirus (HMPV). The development process involved performing a titration of each virus for TCID 50 calculations and determining the optimal HAE infection time in a time course experiment, with every step of the process automated to increase speed and accuracy. Following infection of the HAE tissues, the amount of infectious virus in HAE supernatant was assessed in a Cytopathic Effect (CPE) or Virus Titer Reduction (VTR) assay in an appropriate cell line for that particular virus. The optimized assays consistently showed Z' values > 0.7 and were used to test reference compounds relevant to each antiviral assay. The assay development process and representative results for H3N2 A/Udorn/72 and RSV Long strain will be presented to highlight the benefits of miniaturizing HAE assays from individual wells into a 96-well format, thereby providing a high-throughput solution for human 3D in vitro respiratory tissue models. State of Alabama Innovation Fund (Project number 15803.12.01)

A High-Throughput Human Tissue Model for Respiratory Viruses

High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro

Rational Lung Tissue and Animal Models for Rapid Breath Tests to Determine Pneumonia and Pathogens

A Three-Dimensional Human Tissue-Engineered Lung Model to Study Influenza A Infection.

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes As an in Vitro Model for Coxsackievirus B3-Induced Myocarditis and Antiviral Drug Screening Platform

A High-Throughput, High-Containment Human Primary Epithelial Airway Organ-on-Chip Platform for SARS-CoV-2 Therapeutic Screening

Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents

Human Multi-Compartment Airways-on-Chip Platform for Emulating Respiratory Airborne Transmission: From Nose to Pulmonary Acini

High Throughput Screening with a Primary Human Mucociliary Airway Model Identifies a Small Molecule with Anti-SARS-CoV-2 Activity

3D tissue-engineered lung models to study immune responses following viral infections of the small airways

The Human Nose Organoid Respiratory Virus Model: an Ex Vivo Human Challenge Model To Study Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pathogenesis and Evaluate Therapeutics

Development of robust antiviral assays using relevant apical-out human airway organoids

Advanced in vitro and ex vivo models provide a suitable platform for the evaluation of antiviral small molecules against human parainfluenza virus 3

Recent advances in human respiratory epithelium models for drug discovery

Building a human lung from pluripotent stem cells to model respiratory viral infections

Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System

Virus neutralization assays for human respiratory syncytial virus using airway organoids

A three-dimensional A549 cell culture model to study respiratory syncytial virus infections

Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection

Small molecule-directed differentiation of submerged-cultured human nasal airway epithelia for respiratory disease modelling